Revolution Medicines (RVMDW) Interest Expenses (2019 - 2026)
Revolution Medicines (RVMDW) posted quarterly Interest Expenses of $1.2 billion for Q1 2026, up 584.85% year-over-year from $170.7 million in Q1 2025, and up 9636.02% quarter-over-quarter from -$12.3 million in Q4 2025.
Revolution Medicines (RVMDW) Interest Expenses (2019 - 2026) Analysis & Trends
Revolution Medicines' Interest Expenses history runs 8 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- In Q1 2026, Interest Expenses rose 584.85% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 584.85% YoY), while the FY2025 annual figure was $885.5 million, up 220.44% from the prior year.
- Interest Expenses for Q1 2026 stood at $1.2 billion, up from -$12.3 million in the prior quarter.
- The five-year high for Interest Expenses was $1.2 billion in Q1 2026, with the low at -$12.3 million in Q4 2025.
- The 5-year median for Interest Expenses is $108.7 million (2023), against an average of $194.5 million.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses jumped 13257.14% in 2023, then tumbled 336.38% in 2025.
- Revolution Medicines' Interest Expenses stood at -$1.4 million in 2022, then surged by 13257.14% to $184.2 million in 2023, then plunged by 101.52% to -$2.8 million in 2024, then sank by 336.38% to -$12.3 million in 2025, then surged by 9636.02% to $1.2 billion in 2026.
- Business Quant data shows RVMDW's Interest Expenses at $1.2 billion in Q1 2026, -$12.3 million in Q4 2025, and $328.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Revolution Medicines | 2.45 Bn | 2.45 Bn | - | 23.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.70 Bn |
| Jun 30, 2026 | 2.70 Bn |
| Mar 31, 2026 | 1.17 Bn |
| Mar 31, 2026 | 1.17 Bn |
| Dec 31, 2025 | -12.26 Mn |
| Dec 31, 2025 | -12.26 Mn |
| Sep 30, 2025 | 328.12 Mn |
| Sep 30, 2025 | 328.12 Mn |
| Jun 30, 2025 | 204.76 Mn |
| Jun 30, 2025 | 204.76 Mn |
| Mar 31, 2025 | 170.68 Mn |
| Mar 31, 2025 | 170.68 Mn |
| Dec 31, 2024 | -2.81 Mn |
| Dec 31, 2024 | -2.81 Mn |
| Sep 30, 2024 | 312.82 Mn |
| Sep 30, 2024 | 312.82 Mn |
| Jun 30, 2024 | 232.90 Mn |
| Jun 30, 2024 | 232.90 Mn |
| Mar 31, 2024 | 154.05 Mn |
| Mar 31, 2024 | 154.05 Mn |